(Q42947254)

11 November 2017

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial (English)

1 reference

11 November 2017

0 references

1 reference

7

Stefan Zeuzem

1 reference

11 November 2017

Ulrich F H Leuschner

1

1 reference

11 November 2017

Birgit Lindenthal

2

1 reference

11 November 2017

Günter Herrmann

3

1 reference

11 November 2017

Joachim C Arnold

4

1 reference

11 November 2017

Martin Rössle

5

1 reference

11 November 2017

Hans-Jörg Cordes

6

1 reference

11 November 2017

Jasper Hein

8

1 reference

11 November 2017

Thomas Berg

9

1 reference

11 November 2017

NASH Study Group

10

1 reference

11 November 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

11 November 2017

1 reference

11 November 2017

52

1 reference

11 November 2017

472-479

1 reference

11 November 2017

2

1 reference

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

11 November 2017

1 reference

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

21 January 2018

1 reference

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

Plasma adiponectin is decreased in nonalcoholic fatty liver disease.

21 January 2018

1 reference

4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells

21 January 2018

1 reference

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study

21 January 2018

1 reference

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial

21 January 2018

1 reference

Hepatic effects of dietary weight loss in morbidly obese subjects.

21 January 2018

1 reference

Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis

21 January 2018

1 reference

Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go?

21 January 2018

1 reference

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

Primary biliary cirrhosis

21 January 2018

1 reference

Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease

21 January 2018

1 reference

Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?

21 January 2018

1 reference

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

21 January 2018

1 reference

7 January 2021

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

1 reference

7 January 2021

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

1 reference

7 January 2021

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

7 January 2021

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

1 reference

7 January 2021

Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23727

1 reference

11 November 2017

1 reference